We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
The study showing how thrombocytopenia increases the risk of thrombosis in patients with antiphospholipid syndrome has been considered the best paper published in 2021.
The Societat Catalanobalear de Medicina Interna (SCBMI) has awarded a study led by Dr. Josep Pardos Gea, investigator of the Systemic Diseases research group of the Vall Hebron Research Institute (VHIR) led by Dr. Jaume Alijotas Reig, with the Joan Vivancos award for the best article published during 2021. The study, published in the journal Rheumatology (Oxford), establishes that having persistent thrombocytopenia, i.e. a lower than the usual number of platelets, is a major risk factor for thrombosis in patients with antiphospholipid syndrome (APS).
This study has followed up and compiled data from a subgroup of 114 patients diagnosed with APS, treated and monitored at the Systemic Autoimmune Diseases Unit of the Vall d'Hebron University Hospital from 1980 to 2018. Dr. José Pardos Gea emphasizes that the association between thrombocytopenia and APS is only apparent when data are reviewed over a long historical view and therefore had not been confirmed until this study.
The analysis establishes that the risk of thrombosis and, therefore, lower patient survival occurs in cases of moderate and mild thrombocytopenia, with a range of 50 to 150 x109 platelets/liter, while the relationship is not so clear with severe thrombocytopenia. From the study, we see the need to take this factor into account when monitoring patients, as well as when studying the pathogenesis of the disease and developing therapeutic strategies.
The Systemic Diseases Clinical Unit, as well as the Systemic Diseases Research Unit, has been working with this pathology for over 40 years. "We monitor almost 900 patients with SAF and we also lead the European EUROAPS registry where there are over 2,000 cases. We also participate in other international projects such as APS-ACTION, CORA or SKY-LARK. We have the expertise, this allows us to treat patients better. We continue working and studying these diseases," says Dr. Jaume Alijotas Reig.
The SCBMI is a non-profit association that is part of the Academy of Medical and Health Sciences of Catalonia and the Balearic Islands and brings together specialists in Internal Medicine throughout the territory. Each year they give the Joan Vivancos Award for the best article published during the previous year; the Bartolomé Cabrer Award for the best Doctoral Thesis for the degree of Doctor of Medicine read during the previous year; and the award to the young researcher with the best publication.
Joan Vivancos award is given to the best article published on 2022
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Vall d’Hebron University Hospital Foundation – Research Institute. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.